Roche wins reprieve as Novartis biosimilar delayed in U.S.

LONDON/ZURICH (Reuters) - Roche has won a reprieve an expected deluge of cheaper versions of its biotech cancer drugs as U.S. regulators knocked back a biosimilar form of rituximab from Swiss rival Novartis.